NMRD NEMAURA MEDICAL

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

Nemaura Medical to Present at the Sidoti & Co. Micro Cap Virtual Conference

Loughborough, England, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle and weight reduction programs, announces that CEO Dr. Faz Chowdhury will present a corporate overview at the Sidoti & Co. Micro Cap Virtual Conference being held on January 18 -19, 2023.

Presentation Date: January 19, 2023

Time: 9:15am EST

Webcast Link below:

Dr. Chowdhury will be available for one-on-one investor meetings throughout the conference. Investors can attend the conference and request a meeting with Dr. Chowdhury by registering for the conference using the link below:

About Nemaura Medical, Inc.

Nemaura Medical Inc. is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently also commercializing sugarBEAT® and proBEAT. sugarBEAT®, a CE mark approved Class IIb medical device, as a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT combines non-invasive glucose data processed using artificial intelligence under a digital healthcare subscription service that has been launched in the U.S. as a general wellness product as part of its BEAT® diabetes program that is currently undergoing pilot studies.

The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023.

For more information, please visit .

Media Contact:

Jules Abraham

CORE IR

917-885-7378

Investor Contact:

Bret Shapiro - Senior Managing Partner

CORE IR

561-479-8566



EN
11/01/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NEMAURA MEDICAL

 PRESS RELEASE

Important Update on Listing Status and Strategic Direction

Important Update on Listing Status and Strategic Direction Loughborough, UK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs, is providing a crucial update regarding recent decisions that will impact Nemaura Medical's listing status on The Nasdaq Capital Market and our broader strategic direction. Background: After thorough analysis, Nemaura Medical’s Board of Directors and management team have made the strategic decision to accept Nasdaq’s determination to ...

 PRESS RELEASE

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision

Nemaura Medical Inc. Receives Positive Nasdaq Listing Decision Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market. ...

 PRESS RELEASE

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility ...

Nemaura Medical Inc. Secures $10 Million Non-Dilutive Credit Facility to Fuel Strategic Growth Loughborough, UK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce the execution of a strategic agreement for a $10 million credit facility which is expected to support the Company’s strategic growth plans. Recognizing the challenges associated with equity sales, particularly in the small-cap landscape on the Nasdaq, Nemaura Med...

 PRESS RELEASE

Nemaura Launches Direct to Consumer Offering of Metabolic Health Progr...

Nemaura Launches Direct to Consumer Offering of Metabolic Health Program in Combination with GLP-1 Weight Loss Drugs Company CEO to discuss development at 1pm EST on 15th November 2023, at the Sidoti Virtual Investor Conference Loughborough, UK, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, developer of a daily wear non-invasive glucose sensor, and digital healthcare programs today announced the UK launch of its ground-breaking approach to metabolic health and weight management by integrating continuous glucose monitoring (CGM) with its behavioral change program, Miboko, complemen...

 PRESS RELEASE

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provide...

Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update Loughborough, England, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, today released its financial results for the quarter ended September 30, 2023 and provided a business update. Corporate Highlights:  1.The Company continued to support its UK licensee with its endeavours to ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch